Company Overview
Company Type: Private Company
Website: ibiosolutions.com
Number of Employees: -
Year Founded: 2012
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Immune Biosolutions Inc. develops and produces polyclonal and recombinant chicken antibodies as research and diagnostic tools, nutraceuticals, and antibody-based drugs to explore and resolve various health issues worldwide. The company offers primary, secondary, and conjugated antibodies, as well as blocking and detection reagents. It sells its products through distributors in Atlanta, Georgia; Little Rock, Arkansas; San Diego, California; Singapore; Heyford, United Kingdom; Tokyo And Ibaraki, Japan; Aachen, Germany; Shanghai, China; Hong Kong; Melbourne, Australia; and Seongnam-Si, South Korea, as well as online. The company was founded in 2012 and is based in Sherbrooke, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Paquet, Luc 
Chief Executive Officer
Larrivée, Jean-François
Chief Operating Officer and Vice-President
Gaudreau, Simon
Chief Scientist and Vice-President
Leduc, Frédéric 
Chief Business Development Officer

Key Board Members
Name
Title
Proulx, Louise 
Chair of the Board of Directors


Primary Industry Classification
Biotechnology


Primary Office Location
1497, rue Montmartre | Sherbrooke, QC | J1N 3W8 | Canada
Phone: 819-564-5283   Fax: 855-346-3449

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Accélérateur de création d'entreprises technologiques
-
Unknown
-
-
Anges Québec
-
Unknown
-
-
BoxOne Ventures
-
Unknown
-
-
Fonds régional de solidarité FTQ Estrie
-
Unknown
-
-

Prior Investors
W Investments


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Key Developments
Date
Event Type
Headline
Aug-21-2023
Product-Related Announcements
Immune Biosolutions - A Step Closer to the First Inhaled Antibody Treatment for COVID-19
Jan-10-2022
Product-Related Announcements
Immune Biosolutions Reports lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron
Nov-02-2021
Executive/Board Changes - Other
Immune Biosolutions Inc. Appoints Frédéric Leduc as Chief Business Development Officer
Nov-02-2021
Executive Changes - CEO
Immune Biosolutions Inc. Appoints Luc Paquet as Chief Executive Officer
Oct-19-2021
Product-Related Announcements
Immune Biosolutions Inc. Announces the Start of Phase I Clinical Trial for its Immunotherapy (IBIO123) Treatment, Whose Antibodies Have the Potential to Neutralize and Eliminate COVID-19 and its Variants


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 15, 2023 03:59 AM
Immune Biosolutions Inc.
Immune Biosolutions Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
20
GlobalData

Sep 14, 2023 09:15 PM
Immune Biosolutions Inc.
Immune Biosolutions Inc
Reports
39
GlobalData

Jun 15, 2023 11:24 PM
Immune Biosolutions Inc.
Immune Biosolutions Inc
Reports
36
GlobalData

Jun 09, 2023 09:28 AM
Immune Biosolutions Inc.
Immune Biosolutions Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
19
GlobalData

Mar 15, 2023 03:06 AM
Immune Biosolutions Inc.
Immune Biosolutions Inc
Reports
38
GlobalData

Mar 10, 2023 06:28 AM
Immune Biosolutions Inc.
Immune Biosolutions Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
19
GlobalData

Dec 14, 2022 05:36 PM
Immune Biosolutions Inc.
Immune Biosolutions Inc
Reports
38
GlobalData

Dec 10, 2022 03:40 AM
Immune Biosolutions Inc.
Immune Biosolutions Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
19
GlobalData

Sep 23, 2022 06:57 PM
Immune Biosolutions Inc.
Immune Biosolutions Inc
Reports
36
GlobalData

Sep 15, 2022 12:12 AM
Immune Biosolutions Inc.
Immune Biosolutions Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
20


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Proulx, Louise 
Chair of the Board of Directors
819-564-5283
855-346-3449

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Paquet, Luc 
Chief Executive Officer
819-564-5283
855-346-3449

Larrivée, Jean-François
Chief Operating Officer and Vice-President
819-564-5283
855-346-3449
-
Gaudreau, Simon
Chief Scientist and Vice-President
819-564-5283
855-346-3449
-
Leduc, Frédéric 
Chief Business Development Officer
819-564-5283
855-346-3449

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
